What is a bone‑marrow‑suppressor disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Bone Marrow Suppressor Disease?

Bone marrow suppressor disease most commonly refers to myelodysplastic syndromes (MDS), a group of clonal hematopoietic stem cell disorders characterized by ineffective bone marrow function leading to blood cytopenias (low blood counts) and risk of progression to acute myeloid leukemia. 1

Core Definition and Pathophysiology

MDS represents the primary disease category when discussing bone marrow suppression as a disease entity rather than a side effect. These are malignant conditions where:

  • Clonal stem cell dysfunction causes the bone marrow to produce abnormal, dysplastic blood cells that die prematurely in the marrow (ineffective hematopoiesis) 1
  • Cytopenias develop affecting red blood cells (anemia), white blood cells (neutropenia), and/or platelets (thrombocytopenia) 2
  • Progression risk exists with one-fourth to one-third of cases evolving to acute myeloid leukemia 1

The pathophysiology involves a multi-step process including cytogenetic abnormalities, gene mutations, bone marrow microenvironment dysfunction, and widespread gene hypermethylation at advanced stages 1.

Epidemiology and Risk Factors

MDS predominantly affects elderly patients:

  • Median age at diagnosis: 70 years 1, 2
  • Incidence: 4 cases per 100,000 population annually, rising to 40-50 per 100,000 in those aged ≥70 years 1, 2
  • Less than 10% of cases occur in patients younger than 50 years 1

Known Etiologic Factors (15% of cases):

Primary causes:

  • Previous chemotherapy exposure (especially alkylating agents, purine analogues) 2
  • Prior radiotherapy or ionizing radiation 2
  • Occupational benzene exposure 2
  • Tobacco smoking 2
  • Inherited predisposition (particularly in young adults with family history of MDS, AML, or aplastic anemia) 1

Secondary MDS (therapy-related) typically presents with poor prognostic features including complex cytogenetic abnormalities involving chromosomes 5,7, and/or 17p 1, 2.

Diagnostic Criteria

Diagnosis requires:

  • Peripheral blood counts showing cytopenias 1, 2
  • Bone marrow examination demonstrating:
    • Dysplasia in one or more myeloid lineages (≥10% of cells) 2
    • Variable blast percentage (<5% to 19% depending on subtype) 2
    • Usually hypercellular marrow (occasionally hypocellular) 1
  • Cytogenetic analysis of bone marrow cells 2
  • Bone marrow biopsy strongly recommended at initial diagnosis 2

Role of Immune Dysregulation

Recent evidence highlights that MDS involves significant immune dysfunction beyond the clonal myeloid disorder:

  • Myeloid-derived suppressor cells (MDSCs) are markedly expanded in MDS bone marrow and contribute to disease pathogenesis 3, 4
  • These cells overproduce suppressive cytokines (IL-10, TGF-β) and function as apoptotic effectors targeting normal hematopoietic progenitors 4
  • The S100A9/CD33 pathway drives MDSC expansion and contributes to ineffective hematopoiesis 4
  • Immune-mediated suppression of normal hematopoiesis contributes to peripheral cytopenias 5

Clinical Distinction

Important caveat: The term "bone marrow suppression" is also commonly used to describe chemotherapy-induced cytopenias 6, which is a side effect rather than a disease. When discussing bone marrow suppressor disease, the reference is specifically to MDS and related clonal myeloid disorders, not treatment-related toxicity.

The WHO classification system divides MDS into multiple subtypes based on dysplasia patterns, blast percentages, and cytogenetic findings 2, with prognosis determined by the International Prognostic Scoring System (IPSS/IPSS-R) incorporating blast percentage, cytogenetics, and number/severity of cytopenias 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.